Log in
NYSE:MOR

MorphoSys Stock Forecast, Price & News

$34.23
+0.49 (+1.45 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$33.97
Now: $34.23
$34.74
50-Day Range
$30.28
MA: $31.71
$34.74
52-Week Range
$18.21
Now: $34.23
$37.96
Volume32,675 shs
Average Volume117,441 shs
Market Capitalization$4.50 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone49 89 89927 0

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$4.50 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$34.23
+0.49 (+1.45 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys (NYSE:MOR) Frequently Asked Questions

How has MorphoSys' stock been impacted by COVID-19 (Coronavirus)?

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MOR shares have increased by 35.5% and is now trading at $34.23.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of MorphoSys?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for MorphoSys
.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for MorphoSys
.

How were MorphoSys' earnings last quarter?

MorphoSys AG Unsponsored ADR (NYSE:MOR) released its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.03. The firm had revenue of $20.26 million for the quarter, compared to the consensus estimate of $10.84 million.
View MorphoSys' earnings history
.

Who are some of MorphoSys' key competitors?

What other stocks do shareholders of MorphoSys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include NVIDIA (NVDA), AbbVie (ABBV), DexCom (DXCM), Micron Technology (MU), Roku (ROKU), ACADIA Pharmaceuticals (ACAD), Accenture (ACN), Advanced Micro Devices (AMD), Activision Blizzard (ATVI) and Bristol-Myers Squibb (BMY).

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 60)
  • Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
  • Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
  • Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
  • Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 61)

When did MorphoSys IPO?

(MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the New York Stock Exchange (NYSE) under the ticker symbol "MOR."

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $34.23.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $4.50 billion.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

How can I contact MorphoSys?

The company can be reached via phone at 49 89 89927 0.

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.